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The HIV wasting syndrome represented the face of HIV/AIDS before the advent of highly active antiretroviral therapy (HAART).
Although the incidence of wasting has declined since the introduction of HAART, weight loss remains common in patients
receiving HAART, especially in the setting of a failing HAART regimen. As we are not aware of any previous reports from Nigeria,
we report a case of the classical wasting syndrome in a Nigerian female who had both virological and immunological HAART
failure due to poor adherence. The inﬂuence of a failing HAART regimen, socioeconomic status, and other clinical variables in the
wasting syndrome are discussed.
1.Introduction
HIV wasting syndrome has been deﬁned by the Centre
for Disease Control (CDC), USA, as involuntary weight
loss greater than 10% of baseline weight associated with
either chronic diarrhoea for at least 30 days or chronic
weakness or documented fever for at least 30 days in the
absence of a concurrent illness or condition other than
HIV infection that could explain ﬁndings (e.g., tuberculosis,
cryptosporidiosis, or other speciﬁc enteritis) [1] Although
the wasting syndrome has declined since the introduction of
highly active antiretroviral therapy (HAART) [2, 3], weight
lossstillremainsacommoncauseofmorbidityandmortality
in HIV-infected patients receiving HAART [4, 5].
In Nigeria, weight loss and severe wasting often compli-
cates HIV/AIDS [6–9], but we are not aware of any report
speciﬁcally describing the risk factors, features, clinical
course, and outcome of the wasting syndrome as deﬁned by
CDC, especially in patients receiving HAART. We describe
a case of the classical wasting syndrome in an unemployed
NigerianwidowanddiscusstheinﬂuenceofafailingHAART
regimen, socioeconomic status, and other clinical variables
in the wasting syndrome.
2. Case History
A 32-year-old HIV-1-infected widow was admitted to our
tertiary hospital with a 6-month history of progressive
lethargy, anorexia, recurrent fever, vomiting, watery non-
bloodydiarrhoea,andprogressiveweightloss.Shewentfrom
50kg to 21kg in 5 months, a 42% weight loss. She was
unemployed and had no source of regular income to care
for herself or her 3 children. Hence, her meals before and
during her illness were irregular and consisted mainly of
carbohydrate diet.
On examination, she was conscious, prostrated, severely
wasted with generalised wasting of muscle groups, loss of
subcutaneous fat, and prominence of bones. There was no
evidenceoflocalisedsubcutaneousfatatrophyorfatredistri-
bution. Her body mass index was 10.2kg/m2, and the mid-
upper arm circumference was 10cm (Figures 1 and 2). She
had hypoproteinemic hair and skin changes, dehydration,
fever (37.8◦C), pallor, and oropharyngeal candidiasis but
no lymphadenopathy. Chest, cardiovascular, and abdominal
examinations were normal.
She was on HAART (Zidovudine, Lamivudine, Nevi-
rapine) for 16 months but adherence was poor (<70%).2 Case Reports in Medicine
Figure 1
On HAART, her viral reduced from 421,000copies/ml to
41,000copies/ml, but CD4+ T cell count dropped from
168cells/ul to 34cells/ul. Full blood count revealed micro-
cytichypochromicanaemia(packedcellvolumeof24%)and
leukopenia of 1.2 × 103/ul. Three separate stool microscopy
and culture, including modiﬁed Ziehl Neelsen stain for cryp-
tosporidiosis and isosporiasis, were all negative for parasites
and bacteria, and also negative for cells such as red blood
cells and white blood cells. Apart from mild hypokalemia
(serum potassium of 3.0mmol/l) and low serum albumin of
22mmol/l, other renal and liver function tests were normal.
Chest X-ray and abdominopelvic ultrasound were normal.
Hepatitis B and C serology and blood ﬁlm for malaria
parasites were also negative.
She was rehydrated, and diarrhoea was controlled with
an antimotility agent (tablets loperamide) after empiric
treatment for infectious diarrhoea using tablets albendazole
400mg daily for 3 days, intravenous ciproﬂoxacin 500mg
twice daily for one week, and tablets tinidazole 2g start.
Oral ﬂuconazole 200mg daily for oral thrush, prohylactic
septrin 960mg daily, multivitamins, and haematinics were
also given.
She had intensive nutritional rehabilitation with locally
available high protein and high energy diet as well as fruits
and vegetables. Speciﬁcally, “kwashiokor pap” or “kwashi
pap”,ahighproteinlocaldietmadeupofamixtureofground
guinea corn, ground soya bean, and ground crayﬁsh, ground
dried ﬁsh, roasted ground groundnuts, and boiled water was
given orally three to ﬁve times per day, along with variety of
other local foods.
Figure 2
Additional adherence counselling was given, and ART
was switched to Emtricitabine/Tenofovir and Nevirapine on
account of anaemia.
All symptoms gradually resolved and she gradually
regained her physical strength with improved physical activ-
ity. At the end of 6 weeks, her weight increased by about
8kg and she was thereafter discharged to the social welfare,
nutritional, and adherence counselling unit.
3. Discussion
The pathophysiological mechanisms underlying the HIV
wastingsyndromearerelatedtothreemajorfactorsincluding
inadequate nutrient intake, nutrient malabsorption, and
disturbances in metabolism (reviewed in references [10–
12]).
The burden of HIV infection impoverishes [13]; in
sub-Saharan Africa, women and children are the most
aﬀected and they are more likely to suﬀer from neglect,
discrimination, and abuse [14]. Poor socioeconomic status
has been shown to be a strong determinant of weight loss
in HAART experienced HIV-infected patients [4]. These
patients were found not to be able to aﬀord regular high-
protein and high-calorie meals needed for weight gain and
for restoration of lost body cell mass. In the reported
case, poverty precluded adequate intake of nutritious meals
before and during patient’s illness and this problem was
compounded during the illness by anorexia, oral sores,Case Reports in Medicine 3
vomiting, and diarrhoea. Anorexia may also result from
anxiety and depression, which are both common psychiatric
complications of HIV infection [15]. Other recognised
causes of inadequate nutrient intake include dysphagia and
odynophagia, which may be due to infections of the oral
cavity, posterior pharynx, or oesophagus.
Both micronutrient and macronutrient malabsorption
have been observed in the wasting syndrome, and nutrient
malabsorption may occur with or without diarrhoea [10,
16]. Chronic diarrhoea leading to malabsorption may either
be due to the HIV virus itself (i.e., AIDS enteropathy) or
due to occult opportunistic infections (e.g., Cytomegalovirus,
Clostridium diﬃcile, and Mycobacterium avium intracellular
bacteria, among others) [17]. In AIDS enteropathy, no
speciﬁc pathogen can be isolated from the gut, and the
chronic diarrhoea, motility disturbances, and mucosal atro-
phy accompanying this condition have been attributed to
the direct eﬀects of HIV, especially as viral proteins have
been found in the gut mucosa [18]. AIDS enteropathy is a
diagnosis of exclusion; however, complete exclusion of all
opportunistic causes of diarrhoea in HIV-infected patients is
a challenging task sometimes requiring invasive techniques
[17, 19]. Consequently, the WHO recommends the use
of empiric antimicrobials and constipating drugs such as
loperamide, for treatment of chronic HIV-related diarrhoea
in resource poor settings [20].
By leading to malabsorption and/or changes in pharma-
cokinetics of the ART medications, chronic diarrhoea may
also contribute to HAART treatment failure. In a clinical
study by Brantley et al. [21], AIDS-related diarrhoea and
weight loss were associated with both subtherapeutic plasma
levels of antiretroviral medications and protozoan pathogens
in stool. Hence, in patients receiving HAART, prompt
and eﬀective treatment of chronic diarrhoea is essential to
prevent both weight loss and HAART treatment failure.
Various metabolic abnormalities leading to weight loss
have been described in HIV-infected patients, and these
abnormalities have been attributed to several etiologies
including the HIV virus itself, concomitant opportunistic
infections,cytokinedysregulation,andhormonalimbalances
accompanying HIV infection, as well as ART medications
[10, 11].
A failing HAART regimen leads to persistent viral
replication and progressive immunosuppression as reﬂected
in the CD4 cell count. Correlations have been established
between high HIV viral load, low CD4 cell counts, and
weight loss [4, 22, 23]. In HAART experienced patients with
suppressed plasma viral load, weight loss has been attributed
to the persistence of HIV in peripheral blood monocytes
and macrophages [24]. The persistence of HIV leads to
excessive cytokine activation and dysregulation, and this in
turn triggers various metabolic abnormalities that lead to
weight loss such as increase in resting energy expenditure,
proteolysis, and hypercatabolism. Cytokines may also inhibit
anabolism by causing growth hormone resistance and by
reducing hepatic production of insulin-like growth factor-1,
a messenger of growth hormone [25]. The increase in resting
energy expenditure and cytokine dysregulation in HIV
infection may be intensiﬁed by concomitant opportunistic
infections [10]. Various cytokines, such tumour necrosis
factor α, interleukins-1 (IL-1), IL-6, and interferon gamma,
have been implicated in these metabolic perturbations [11].
By interfering with lipid metabolism in muscle, elevated
levels of proinﬂammatory cytokines such as TNF-α also
lead to muscle weakness and muscle atrophy [26]; both are
characteristics features of the wasting syndrome.
The use of HAART has also been independently associ-
ated with an increase in resting energy expenditure, and this
has been suggested as one of the factors perpetuating weight
lossintheHAARTera[4,10].Althoughsometimeschalleng-
ing to distinguish, even with appropriate body composition
measurements, HAART-induced weight loss often leads to
loss of fat loss and/or fat redistribution (Lipodystrophy) with
little or no loss of lean body mass [10]. Conversely, the
wasting syndrome is characterised by a complex interplay of
lean body and fat loss depending on baseline body weight
and other factors such as gender [10, 27]. With progressive
HIV infection, women lose a higher amount of body fat
relative lean body mass while men lose more LBM than
fat [27]. These gender diﬀerences in weight loss have been
attributed greater premorbid fat stores in women than men,
as well as due biological and hormonal factors [27].
Hypogonadism, represented by low levels androgen such
as testosterone, may accompany HIV infection in men [28],
anditmaybeasaresultofthesuppressiveeﬀectsofcytokines
on testicular steroidogenesis, as well as due to functional
disorder of the hypothalamus and/or primary testicular
failure [29]. Androgen deﬁciency inhibits protein synthesis
and this may favour a greater loss of muscle mass relative to
fat mass in men. In women, testosterone levels are normally
low and although androgen deﬁciency has been reported in
some women with weight loss, their contribution to weight
loss in women is less understood [30].
Intensive nutritional rehabilitation to prevent or reverse
weight loss remains the cornerstone of management of
the wasting syndrome [10, 12]. The aims are to improve
appetiteandnutrientabsorptionbyaddressingallimmediate
causes of anorexia and malabsorption, such as oral sores and
diarrhoea, to improve intake of adequate calories made up of
high-proteinandlow-fatmealsinadditiontomicronutrients
supplementation, and to correct psychosocial issues that
aﬀect nutrient intake such as poverty and depression, by
providing social and psychological support. In view of the
principal role of HIV in the pathogenesis of the wasting
syndrome, eﬀective HAART aimed at reducing viral load
to undetectable levels and sustaining immune restoration as
reﬂected in improving CD4 cell count is indispensable [12].
In combination with adequate caloric intake, ﬁtness
training by progressive resistance exercises (e.g., lift of
light weights and body building exercises) increases muscle
function and strength, as well as lean body mass and weight
[31]. Conversely, aerobic exercises (e.g., walking, jogging,
and running) may result in little or no increase in body mass
or weight.
Pharmacological treatments are usually reserved for
patients who fail nutritional therapy. Appetite stimulants
(e.g., Megestrol acetate), recombinant human growth hor-
mone(Serostim),andandrogenicsteroids(e.g.,testosterone)4 Case Reports in Medicine
in men with hypogonadism have all been approved for
the treatment of the wasting syndrome [12]. Cytokine
modulators (such as thalidomide) have been investigated for
treatment of wasting syndrome, but their success rates have
beenvariable[11,12,32].Thus,theyarenotyetapprovedfor
the management of the wasting syndrome, until convincing
evidence of their eﬃcacy is established in future studies.
4. Conclusion
HIV wasting syndrome is a disorder characterised by mul-
tiple pathophysiological mechanisms, most mediated by the
HIV virus itself and driven by nutritional abnormalities.
HAART treatment failure is an emerging global challenge,
especiallyindevelopingcountrieswhereHIVinfectionisstill
endemic and the use of HAART is being scaled up [33]. A
failing HAART regimen leads to HIV persistence and acting
together with psychosocial issues such as poverty, it sets the
stage for the re-emergence AIDS deﬁning illness such as the
wasting syndrome.
To prevent or reverse the resurgence of AIDS deﬁning
illness such as the wasting syndrome in this HAART era,
ensuring eﬀective uninterrupted HAART, socioeconomic
empowerment of HIV-infected patients, and prevention
of opportunistic infections are priorities for developing
c o u n t r i e ss u c ha sN i g e r i a .
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